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Previous work has shown that red blood cells (RBCs) reduce nitrite to NO under conditions of low
oxygen. Strong support for the ability of red blood cells to promote nitrite bioactivation comes from using
platelet activation as a NO-sensitive process. Whereas addition of nitrite to platelet rich plasma in the
absence of RBCs has no effect on inhibition of platelet activation, when RBCs are present platelet acti-
vation is inhibited by an NO-dependent mechanism that is potentiated under hypoxia. In this paper, we
demonstrate that nitrite bioactivation by RBCs is blunted by physiologically-relevant concentrations of
nutrients including glucose and the important signaling amino acid leucine. Our mechanistic in-
vestigations demonstrate that RBC mediated nitrite bioactivation is largely dependent on nitrosation of
RBC surface proteins. These data suggest a new expanded paradigm where RBC mediated nitrite
bioactivation not only directs blood ﬂow to areas of low oxygen but also to areas of low nutrients. Our
ﬁndings could have profound implications for normal physiology as well as pathophysiology in a variety
of diseases including diabetes, sickle cell disease, and arteriosclerosis.
& 2016 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Although nitrite was once considered to be inert in human
physiology [1], several studies have shown that, in fact, nitrite acts
as a vasodilator under hypoxic conditions, protects against is-
chemic reperfusion injury, and reduces platelet activation along
with other biological and therapeutic actions [2–10]. In 2003, we
and others showed that slightly supraphysiological levels of in-
fused nitrite increased forearm blood ﬂow [2]. Importantly, the
increases in blood ﬂow were potentiated during exercise sug-
gesting that nitrite is preferentially bioactivated under hypoxic
and mildly acidic conditions so that nitrite bioactivation helps
direct blood ﬂow to where it is needed [2]. We hypothesized thatB.V. This is an open access article u
n; PRP, platelet rich plasma;
tetramethylimidazoline-1-
transporter; CSNO, S-ni-
; DTNB, 5,5′-Dithiobis(2-ni-
cs, Wake Forest University,
ro).nitrite-mediated vasodilation was due to deoxygenated hemoglo-
bin (Hb) in the red blood cell (RBC) which reduces nitrite to NO as
worked out by Doyle and others [11],
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A major challenge to our hypothesis is that NO rapidly reacts
with oxygenated Hb to form nitrate or binds deoxygenated Hb so
that NO export from the RBC is theoretically extremely inefﬁcient
or impossible [2]. Thus, several alternative pathways have been
suggested where intermediate or alternate species, such as a ni-
trosothiol or N2O3, are formed in the reaction of nitrite and Hb that
could carry NO activity from the RBC to the smooth muscle or
other targets [12–16].
Several other enzymatic and non-enzymatic systems have been
proposed to account for nitrite bioactivity that do not involve the
RBC [17–21]. However, studies conducted using aortic rings
showing potentiation of vessel relaxation when nitrite is com-
bined with deoxygenated RBCs or Hb support a role of the RBC and
deoxygenated Hb in nitrite's ability to effect vasodilation [2,22,23].nder the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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has come from the work of Schechter and colleagues where it was
shown that nitrite alone in platelet rich plasma (PRP) does not
affect platelet activation or aggregation, but when RBC were pre-
sent, platelet activity was inhibited [7]. The effect of RBC was en-
hanced upon deoxygenation and the effect was abrogated in the
presence of an NO scavenger [7]. These results suggest RBC are
capable of producing NO activity from nitrite which reduces pla-
telet activity via the established pathway of NO-mediated soluble
guanylate cyclase activation and cGMP signaling [24–27]. Although
other RBC associated enzymes have been suggested to be re-
sponsible for nitrite bioactivation [18,19,28], we have recently
provided evidence that Hb is indeed the main erythrocytic nitrite
reductase [29].
In this paper, we use nitrite-mediated inhibition of platelet
activation to demonstrate a role for glucose and leucine in mod-
ulating erythrocytic bioactivation of nitrite. We further explore the
mechanism of erythrocytic bioactivation of nitrite and have ex-
plored the role of cell-surface protein nitrosation in RBC.2. Materials and methods
2.1. Materials
Blood was drawn from volunteers after providing informed
consent under a protocol approved by the Wake Forest University
School of Medicine Internal Review Board. EZ-Link
Maleimide-PEG2-Biotin, micro BSA reagent and C18 spin columns
were purchased from Thermo Scientiﬁc. Pre-made 4–20% linear
gradient SDS gels, Avidin-HRP and Avidin-HRP substrate were
purchased from Bio-Rad. Protease inhibitor cocktail was purchased
from Sigma. Glucose colorimetric assay kit was purchased from
Cayman chemicals. Pac-1 and CD 61 monoclonal antibodies were
purchased from Becton Dickinson Immunocytometry systems.
2.2. Platelet activation
Platelet activation was measured as described previously using
PAC-1 and CD61 antibodies with data collected using a BD Sciences
FACSCalibur ﬂow cytometer [29]. Inhibition of platelet activation
by deoxygenated RBCs and nitrite was evaluated by adding the
deoxygenated RBCs and nitrite to PRP as described previously [29].
2.3. Time resolved absorption spectroscopy
Time resolved absorption was performed similarly to that de-
scribed previously [29]. Brieﬂy, samples were prepared in 1 cm
quartz, septum capped cuvettes, purged with nitrogen, and ﬁlled
with 4 mL of 100 mM deoxygenated Hb in the presence or absence
of 1 mM leucine or 10 mM glucose. Nitrite (500 mM ﬁnal con-
centration) was added to each cuvette to initiate the reaction.
Spectra were taken every 180 s at 37° C in a Cary 100 UV–vis
spectrometer. Half-lives were determined by when deoxygenated
Hb fell to 50% of its initial value.
2.4. RBC nitrite uptake kinetics
Fresh blood was centrifuged at 1000 g for 5 min at 25 °C at least
three times until the supernatant was clear, and RBCs were re-
suspended in PBS at a stock concentration of 60% hematocrit (Hct)
and then deoxygenated using nitrogen. Deoxygenated RBCs at 15%
Hct were incubated with 1 mM leucine, 10 mM glucose, or neither
at 37 °C for 15 min before adding nitrite. Nitrite (100 mM ﬁnal
concentration) was injected in each sample. Every 15 min in the
ﬁrst hour and every 30 min in the second hour, a 500 mL aliquotwas taken out and spun at 1000 g for 1 min. Supernatant (5 mL)
was injected to measure extracellular nitrite by a Sievers 280i
Nitric Oxide Analyzer. Nitrite consumption was calculated by the
percentage of nitrite remaining at each time-point divided by the
original nitrite concentration.
2.5. Plasma glucose measurement
Plasma glucose was measured in our assays by glucose colori-
metric assay kit according to the manufacturer's recommendation
using micro plate reader.
2.6. Measurement of S-Nitrosohemoglobin (SNO-Hb)
SNO-Hb was measured using the modiﬁed 2 C assay as de-
scribed previously [30]. All mixtures containing nitrosothiols in-
cluded metal chelation with diethylene triamine pentaacetic acid
and protected from light.3. Results
3.1. Nitrite-mediated inhibition of platelet activation by RBCs in-
volves NO or nitrosothiols
Consistent with previously published work [7], we show that
nitrite combined with deoxygenated RBCs reduces platelet acti-
vation (Fig. 1(A)) and this action is blunted by the NO scavenger 2-
(4-Carboxyphenyl)-4,4,5,5-tetramethylimidazoline-1-oxyl-3-oxide
potassium salt (CPTIO) (Fig. 1(B)). Note that there is substantial
variance in the inter-individual response in platelet activation for a
given amount of the agonist ADP (see for example error bar in
Fig. 1(A) for PRP þ ADP). There will also be variability in nitrite
response. The percentage inhibition by 10 μM nitrite in Fig. 1(A) vs.
B is 5274% vs. 3172%, calculated as [(PRPþADP)
(PRPþADPþNitrite)]/(PRPþNitrite)]. Despite these variances,
these data strongly suggest that bioactivation of nitrite by RBCs
involves NO itself. However, previous work has shown that ni-
trosothiol-mediated inhibition of platelet activation is also in-
hibited by NO scavengers including hemoglobin [31]. Nitrosothiols
are reduced to NO at the surface of, or inside RBCs [31,32]. In Fig. 1
(C), we show that CPTIO signiﬁcantly blunts GSNO-mediated in-
hibition of platelet activation. Importantly, the effects of 10 μM
nitrite are comparable to those of GSNO shown in Fig. 1(C) where
the percentage inhibition was 24711% and 31719% for 10 and
20 μM GSNO respectively. These data suggest that RBC RSNO for-
mation cannot be ruled out as at least part of the nitrite bioacti-
vation mechanism based on effects of CPTIO and that the effect of
nitrite is comparable to other compounds that have been con-
sidered as anti-platelet agents.
3.2. Nitrite-mediated inhibition of platelet activation by RBCs is in-
hibited by leucine and glucose
The L-type amino acid transporter 1 (LAT1) system has been
shown to modulate S-nitrosothiol transport, which is inhibited by
leucine [33–36]. Fig. 2(A) shows the effect of different concentra-
tions of leucine on RBC-nitrite dependent inhibition of platelet
activation. Leucine prevented RBC and nitrite-dependent inhibi-
tion of platelet aggregation at the highest (500 mM, p¼0.006) dose
tested, with trends towards signiﬁcant observed a lower (250 μM)
doses. Leucine had no effect on platelet activation with or without
RBCs in the absence of nitrite (Fig. 2(B)). As leucine is an important
signaling molecule that regulates amino acid and glucose uptake
[37,38], we investigated whether glucose itself would modulate
nitrite bioactivation by RBCs. Fig. 2(C) shows that as little as 1 mM
Fig. 1. Nitrite and NO mediated Inhibition of Platelet Activation. (A) Deoxygenated (deoxy) RBC in presence of nitrite inhibits platelet activation. Human PRP and deoxy
erythrocytes (15% hematocrit) were incubated at 37 °C in presence of 1 μM ADP 71 μM or 10 μM nitrite, *po0.05 and **po0.01 compared to deoxyRBCþPRP. Values are
means7SD (n¼3). (B) ADP induced platelet activation is inhibited by nitriteþdeoxy erythrocytes. Human PRPþdeoxy RBC (15% hematocrit) were incubated with 10 μM
nitrite and 1 μM ADP in the presence and absence of 500 μM CPTIO for ten minutes, *po0.01 comparing to deoxyRBCþPRPþnitrite and deoxyRBCþPRPþnitriteþCPTIO.
Experiments were performed at 37 °C. Data values are means7SD (n¼3). (C) CPTIO inhibits the effect of GSNO on platelet activation. Platelet activation was induced by
10 μM ADP in presence or absence of 200 μM CPTIO, 10 and 20 μM GSNO. 200 μM CPTIO abrogates the GSNO mediated effect on platelets, *po0.04 compared with
PRPþCPTIOþ10 μM GSNO and ɸpo0.01compared with PRPþCPTIOþ20 μM GSNO. All experiments were performed at 37 °C. Data values are means7SD (n¼6).
Fig. 2. Nutrient effect on Nitrite-mediated inhibition of Platelet Activation. (A) Leucine abrogates platelet inhibition mediated by nitrite and deoxyRBC. Different con-
centrations of leucine were preincubated with 10 μM nitrite, PRP and deoxy RBC (15% HCT) at 37 °C for ten minutes, platelets were further activated by 1 μM ADP at 37 °C for
10 min. Leucine concentrations 0.5 and 1 mM signiﬁcantly inhibits nitrite mediated platelet inhibition. *po0.006 and **po0.01 compared to nitriteþdeoxyRBC. Data values
are means7SD (n¼3). (B) Human PRPþdeoxyRBCs were pre-incubated with and without nitrite and leucine for 10 min at 37 °C. After pre-incubation platelets were
activated by 1 μM ADP for ten minutes at 37 °C. Leucine alone has no effect on platelet activation. *po0.001 compared to deoxyRBCsþnitriteþ leucine. Data values are
means7SD (n¼3). (C) Glucose dose dependently abrogates platelet inhibition mediated by nitrite and deoxyRBCs. Different concentrations of glucose were preincubated
with 10 μM nitrite, PRP and deoxy RBC (15% HCT) at 37 °C for 15 min, platelets were further activated by 1 μM ADP at 37 °C for 10 min. Glucose at 5, 10 and 30 mM
signiﬁcantly inhibits nitrite mediated platelet inhibition, po0.002 compared to nitriteþdeoxyRBC. Data values are means7SD (n¼4).
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bioactivation (p¼0.07), that was signiﬁcant at higher tested glu-
cose concentrations. Glucose alone did not affect platelet activa-
tion in the absence of nitrite (Fig. 2(C)). Importantly, we found that
in our assays glucose in PRP is lowered to 3.7 mM, so that addition
of 1 mM glucose in these assays raises glucose up to physiologic
levels. These data show that physiological or slightly supraphy-
siological levels of nutrients blunt nitrite bioactivation by RBCs.
3.3. Effects of leucine and glucose are not due to uptake by RBCs or
reaction with Hb
One potential mechanism for the observed effects of glucose and
leucine on nitrite bioactivation could be direct effects of these nu-
trients on the rate of nitrite reduction by deoxygenated Hb. How-
ever, time resolved absorption experiments revealed no difference
in the kinetics of the deoxygenated Hb (100 mM)/nitrite (500 mM)
reaction with half-lives of the reaction being 2971 min,
2475 min, and 2573 min for control, plus 1 mM leucine andplus10 mM glucose respectively (Fig. 3(A)). In addition, leucine and
glucose had no effect on nitrite uptake by red blood cells (Fig. 3(B)).
3.4. Effects of leucine are not due to nitrosothiol transport
Another possible mechanism for the blunting of RBC mediated
nitrite bioactivation by leucine involves S-nitrosation within the
RBC due to the nitrite/Hb reaction along with inhibition of S-ni-
trosothiol transport either out of the RBC or into the platelet. To
test whether leucine inhibits S-nitrosocysteine (CSNO) export
from RBCs, we loaded RBCs with CSNO (1 mM) and washed ex-
tensively so that only 40 nM CSNO remained in the supernatant
(which is less than that required to affect platelet activation in our
experiments (data not shown)). After washing, we incubated the
SNO-loaded cells in buffer with and without leucine (1 mM). We
then examined the ability of the supernatant (which would con-
tain CSNO exported from the RBC) to inhibit platelet activation. As
shown in Fig. 4(A), leucine shows a trend in blunting CSNO export
from the RBC as demonstrated by the ability of the supernatant to
Fig. 3. Nutrient effects on Hb/nitrite reactivity and RBC uptake. (A) Effect of nutrients on nitrite reduction by Hb. Time resolved absorbance spectra after mixing deoxy
hemoglobin (100 mM) and nitrite (500 mM) in the presence of sodium dithionite (10 mM) with Leucine (1 mM, left top, T1/2¼29 min), Glucose (10 mM, right top,
T1/2¼24 min) and buffer as control (left bottom, T1/2¼25 min). Insets show the percentage of deoxyHb (blue) and HbNO (red) as a function of time. Bar graph shows the
average of half-life of three samples (n¼3). Spectra were recorded at 37 °C every 180 s, and all samples were prepared in PBS buffer, pH 7.4. Neither leucine (p¼0.09) or
glucose (p¼0.53) signiﬁcantly affected the kinetics of the reaction compared to control (paired t-test). (B) Effect on nitrite uptake by red blood cells. Deoxygenated RBCs (15%
Hct) were mixed with nitrite (100 mM) in the presence of Leucine (1 mM, blue diamond), Glucose (10 mM, red square), and buffer as control (green triangle). The nitrite
consumption was calculated by the percentage of nitrite concentration at every time-point over the initial value (n¼3). (For interpretation of the references to color in this
ﬁgure legend, the reader is referred to the web version of this article.)
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statistical signiﬁcance (P¼0.08). Thus, inhibition of CSNO export
from RBCs by leucine is not likely a major factor in the blunting of
inhibition of platelet activation by nitrite. We next evaluatedwhether leucine inhibits CSNO uptake by platelets. In Fig. 4(B), we
show that L-leucine does not have an effect on nitrite-mediated
inhibition of platelet activation by S-nitrosocysteine or NO pro-
duced by an NO donor, DEANONOate (Fig. 4(C)).
Fig. 4. Potential role of uptake and export in Leucine Effects. (A) Leucine does not inhibit CSNO export from erythrocytes. RBC were treated with 1 mM CSNO for an hour,
washed CSNO treated RBC were further incubated with and without 1 mM leucine for 45 min at room temperature, supernatant from these RBCs were collected and used in
the platelet activation assay. CSNO treated RBC supernatant and 2 μM CSNO signiﬁcantly inhibits ADP (1 μM) induced platelet activation (**po0.0001), *po0.002 compared
to PRPþADP. Leucine and CSNO treated RBC supernatant did not signiﬁcantly blunt the platelet inhibition (p¼0.08). Data values are 7SD (n¼4). (B) Leucine does not
abrogate CSNO mediated platelet inhibition. CSNO (20 μM) was added to the PRP in presence and absence of 1 mM leucine and preincubated at 37 °C for 5 min. Platelets
were activated with ADP at 37 °C for 10 min. CSNO show statistically signiﬁcant inhibition of platelets (*po0.004), leucine with and without CSNO has no effect on platelet
activation (ɸp¼0.84). Data values are 7SD (n¼3). (C) Leucine does not inhibit platelet inhibition by the NO donor DEANOate. Platelets were preincubated for 5 min at 37 °C
in presence and absence of 5 μM DEANOate and 0.5 and 1 mM leucine. After preincubation platelets were activated by ADP for 10 min at 37 °C. The NO donor DEANOate
signiﬁcantly inhibits platelet activation, but leucine fails to blunt DEANOate mediated platelet inhibition. Data values are 7SD (n¼3).
Fig. 5. Role of RBC surface nitrosation in nitrite bioactivation. (A) Leucine abrogates CSNO loaded RBCs mediated nitrite bioactivation. RBCs were treated with 1 mM CSNO as
described in Fig. 3(A). Washed CSNO treated RBCs were pre-incubated with 1 mM leucine for 10 min at 37 °C. After pre-incubation platelets were activated by ADP at 37 °C
for another 10 min. Leucine blunts the CSNO RBC mediated platelet inhibition. *po0.03 compared to PRPþCSNO RBCs. **po0.001 compared to deoxyRBCsþPRP. Data
values are means7SD (n¼3). (B) RBC thiol nitrosation inhibited platelet activation. RBCs were incubated with 200 μM of the nitrosating agent SNAP 710 mM NEM for an
hour at room temperature. After incubation, RBCs were washed extensively. Washed SNAP7NEM RBCs were pre-incubated with PRP at 37 °C for 10 min. After pre-
incubation platelets were activated by ADP at 37 °C for 10 min. *po0.02 compared with PRPþRBCs and **po0.04 compared with SNAP RBC. Data values are means7SD
(n¼3). (C) RBC surface thiol oxidation abrogates nitrite mediated platelet inhibition. RBCs were pre-incubated with 2.5 mM DTNB for an hour at room temperature. DTNB
treated RBCs were extensively washed and deoxygenated. 10 μM nitrite was added to the deoxy DTNB RBCs in presence of PRP and incubated for 5 min at 37 °C. Platelets
were activated by ADP at 37 °C for 10 min. *po0.0001 compared to PRPþdeoxyRBCs and ɸp¼0.27 compared to PRPþdeoxyRBCsþDTNB. Data values are means7SD (n¼7).
N. Wajih et al. / Redox Biology 8 (2016) 415–421 4193.5. Nitrite-mediated inhibition of platelet activation by RBCs is de-
pendent on RBC surface nitrosation
We next evaluated whether the RBCs themselves were involved
in leucine-inhibitable, RBC mediated nitrite bioactivation. We re-
suspended the pellet containing CSNO-loaded RBCs and observed
that these cells inhibit platelet activation and leucine blunts the
inhibition (Fig. 5(A)). These data suggest that bioactivation of ni-
trite by RBCs may be due to red cell membrane surface nitrosation.
To further investigate a possible role for surface nitrosation of
RBCs, we employed S-Nitroso-N-acetylpenicillamine (SNAP), a cell
membrane-impermeable nitrosating agent, to surface nitrosate
red blood cells and test whether these cells can inhibit platelet
activation. This experiment was designed to test whether surface
nitrosation of RBCs can result in platelet inhibition (if not, then
RBC-mediated nitrite bioactivation is not likely to involve RBC
surface nitrosation). We conﬁrmed that SNAP would only nitrosate
surface thiols when RBCs are exposed to SNAP vs. CSNO (which
enters cells) by incubating these with RBCs and measuring SNO-
Hb. When RBCs were incubated with 500 μM CSNO for one hour,2.270.6 μM SNO-Hb was formed. When RBCs were treated with
500 μM SNAP for one hour, only 0.0970.03 μM SNO-Hb was de-
tected (n¼3). It should be noted that we found trans-nitrosation
from SNAP and CSNO to Hb have similar efﬁciencies outside the
RBC. We found that when 50 μM CSNO or SNAP was incubated
with 1 mM Hb for one hour, 0.2870.15 μM and 0.2670.003 μM
SNO-Hb was produced, respectively (n¼3). These data are con-
sistent with previous studies examining cellular uptake of SNAP
[39,40]. We thus incubated red blood cells with SNAP, thoroughly
washed the cells, and tested their ability to inhibit platelet acti-
vation. Indeed, these surface nitrosated cells inhibited platelet
activation and their activity was abrogated with prior treatment
with the thiol blocking agent N-Ethylmaleimide (NEM, Fig. 5(B)).
In addition, we found that when red cells were pre-incubated with
the cell-impermeable surface thiol blocking agent 5,5′-Dithiobis(2-
nitrobenzoic acid) (DTNB) and thoroughly washed, nitrite-medi-
ated inhibition of platelet activation by red blood cells was abro-
gated (Fig. 5(C)). These data strongly support the notion that in-
cubation of RBCs with nitrite leads to cell-surface nitrosation and
this action plays a major role in nitrite bioactivation by RBCs.
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The biggest discovery resulting from our work reported above
is that leucine and glucose blunt nitrite bioactivation by red blood
cells (Fig. 2). Whole blood levels of leucine after overnight fast are
about 130 μM [41], but can increase 2–3 fold after a meal [42].
Thus, based on the data shown in Fig. 2(A), physiological levels of
leucine are likely to modulate nitrite bioactivation by RBCs. Like-
wise, as physiological levels of blood glucose range from 4 to
6 mM, and we found levels of glucose in our PRP after RBC addi-
tion to be about 3.7 mM, our data (Fig. 2(C)) show that physiolo-
gical levels of glucose modulate nitrite bioactivation by RBCs. The
extent of modulation by these nutrients requires further study,
particularly at lower pH which occurs in active tissue and also in
which reduction of nitrite by Hb is facilitated [43].
We found that the mechanism of the observed effects of glu-
cose and leucine is not due to modulation of the kinetics of the Hb/
nitrite reaction or nitrite uptake by RBCs (Fig. 3). We also found
that leucine does not affect CSNO mediated inhibition of platelet
activation either by direct interaction with the platelets or through
export of CSNO from the RBC (Fig. 4). We did, however, ﬁnd that
leucine blunts inhibition of platelet activation by CSNO-loaded red
cells themselves (Fig. 5(A)), leading us to explore whether RBC
membrane surface nitrosation may be involved. We found that
surface nitrosated red cells do indeed blunt inhibition of platelet
activation and that oxidation of surface thiols abrogates nitrite-
mediated inhibition of platelet activation by red blood cells.5. Conclusions
In conclusion, our results suggest an expansion of the paradigm
that we and others put forth in 2003 whereby low oxygen tension
leads to Hb deoxygenation bioactivating nitrite so that NO activity
is exported to induce vasodilation and increased blood ﬂow to low
oxygen tissue where it is needed [2]. Our data suggest that RBC
mediated nitrite bioactivation is also targeted to areas of low nu-
trients, further facilitating blood ﬂow to where it is needed, in
metabolically active muscle and other tissues. It is well known that
glucose is absorbed by active muscle and is a very important fuel
for endurance exercise [44,45]. Leucine is an important signaling
amino acid that facilitates insulin-associated glucose uptake [38],
and is a major factor in regulating protein synthesis and increasing
muscle mass [37,42]. Our ﬁndings thus have important implica-
tions for regulation of blood ﬂow during exercise in normal phy-
siology and in pathological conditions that involve poor peripheral
circulation such as peripheral artery disease, heart failure with
preserved ejection, diabetes, and sickle cell disease.Conﬂicts of interest
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